

Psychiatry Grand Rounds

WCM Department of Psychiatry
Psychology CE Announcement

“Paying Attention to ADHD: Focus on Pharmacotherapy”

Timothy E. Wilens, M.D

Chief, Division of Child and Adolescent Psychiatry

Co-Director, Center for Addiction Medicine

MGH Trustees Chair in Addiction Medicine, Massachusetts General Hospital

Professor of Psychiatry, Harvard Medical School

Wednesday, September 27th, 2023

11:00am – 12:30pm

<https://weillcornell.zoom.us/j/92812036154>

Meeting ID: 928 1203 6154

Password: 12345

1.5 CE credit available to WCM Department of Psychiatry full time and voluntary faculty Psychologists and Social Workers who sign in with their full name, attend the majority of the lecture and complete a survey which will be emailed following the completion of the lecture. Note the survey must be completed within 30 days of the lecture. Please contact Stephanie Harper at sth4009@med.cornell.edu for additional CE information

SPEAKER DISCLOSURE:

Dr. Wilens has received royalties from Ironshore, Guilford Press, and Cambridge University for his intellectual property. He DOES NOT INTEND to discuss off-label or investigational use of products or services.

Bio:

Dr. Timothy Wilens is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School. Dr. Wilens earned his MD at the University of Michigan Medical School in Ann Arbor and completed his residency in child, adolescent, and adult psychiatry at Mass General. Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models, digital therapeutics, and the pharmacotherapy of ADHD across the lifespan. He has published more than 325 peer-reviewed articles, concerning these and related topics. He has also coedited more than 80 book chapters, 5 books, and 350 abstracts and presentations for national and international scientific meetings. Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry and is on the editorial boards or is a scientific reviewer for more than 35 journals.

Abstract:

ADHD is increasingly presenting for diagnosis and treatment in young people. Data suggests that up to 9% of young people and 4-5% of adults have ADHD. PHarmacotherapy is among first line treatments. In this session, a review of diagnostic consideration, medication treatments, age groups, and their short- and longer-term outcomes including adverse effects will be reviewed.

Learning Objectives:

1. Discuss the epidemiology of ADHD
2. List newer pharmacotherapy options for ADHD
3. Describe longer-term outcomes of stimulant and nonstimulant treatment of ADHD

References:

1. Newcorn, J. H., Krone, B., & Dittmann, R. (2022). Nonstimulant treatments for ADHD. *Child and Adolescent Psychiatric Clinics of North America*, 31(3), 417–435. <https://doi.org/10.1016/j.chc.2022.03.005>
2. Boland, H., DiSalvo, M., Fried, R., Woodworth, K. Y., Wilens, T., Faraone, S. V., & Biederman, J. (2020). A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. *Journal of psychiatric research*, 123, 21–30. <https://doi.org/10.1016/j.jpsychires.2020.01.006>
3. Childress, A. C., Lloyd, E., Jacobsen, L., Gunawardhana, L., Johnson, S. A., Jr, & Findling, R. L. (2022). Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*, 61(12), 1423–1434. <https://doi.org/10.1016/j.jaac.2022.03.034>
4. Wilens, T. E., & Fusillo, S. (2007). When ADHD and substance use disorders intersect: relationship and treatment implications. *Current psychiatry reports*, 9(5), 408–414. <https://doi.org/10.1007/s11920-007-0053-3>